Article Test

Introduction
Breast cancer is the most common cancer among women worldwide, accounting for about 25% of all cancer cases and 15% of cancer-related deaths among women1. Although advancements in early detection and treatment have significantly improved survival rates, breast cancer remains a major public health concern, especially in low- and middle-income countries (LMICs) where resources for diagnosis and treatment are limited2. This review article discusses the current state of breast cancer research, highlighting advancements in diagnosis, treatment, and prevention, as well as the challenges and future directions.

1.    Breast Cancer Epidemiology and Risk Factors
Breast cancer incidence and mortality rates vary considerably worldwide, with higher rates observed in high-income countries (HICs) compared to LMICs3. This variation is partly due to differences in risk factors, lifestyle, and access to screening and treatment2. Established risk factors for breast cancer include age, gender, family history, hormonal factors (e.g., early menarche, late menopause, and hormone replacement therapy), reproductive factors (e.g., nulliparity and late age at first birth), and lifestyle factors such as alcohol consumption, physical inactivity, and obesity4.
In recent years, research has also identified several genetic factors that increase the risk of breast cancer. The most well-known genes associated with breast cancer risk are BRCA1 and BRCA2, which are responsible for approximately 25% of hereditary breast cancers5. Other genes, such as PALB2, CHEK2, and ATM, have also been implicated in breast cancer susceptibility, albeit with lower penetrance6. Identification of individuals with these genetic mutations allows for targeted prevention strategies, such as increased surveillance, risk-reducing surgery, and chemoprevention7.

2.    Advances in Breast Cancer Screening and Diagnosis
Breast cancer screening aims to detect the disease in its early stages, when treatment is more effective and outcomes are better. Mammography is the most commonly used screening method, with randomized controlled trials demonstrating a 15% to 29% reduction in breast cancer mortality among women aged 50-69 years8. However, mammography has limitations, such as reduced sensitivity in women with dense breasts and an increased risk of overdiagnosis and overtreatment9.

Recent advancements in imaging technology, such as digital breast tomosynthesis (DBT), have shown promise in overcoming some of the limitations of mammography. DBT provides three-dimensional images of the breast, which can improve cancer detection rates and reduce false-positive results compared to conventional mammography10. Additionally, breast magnetic resonance imaging (MRI) has been shown to be more sensitive than mammography for detecting breast cancer in high- risk women, such as those with BRCA mutations11.

Another promising area of research in breast cancer diagnosis is the development of liquid biopsy techniques, which analyze circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), or other tumor-derived biomarkers in blood samples12. Liquid biopsies have the potential to provide real-time information on tumor dynamics, monitor treatment response, and detect minimal residual disease or early recurrence13. However, further research is needed to validate and standardize these techniques before they can be widely implemented in clinical practice.

3.    Advances in Breast Cancer Treatment
Breast cancer treatment has evolved considerably over the past few decades, with the development of targeted therapies and immunotherapies, in addition to the traditional approaches of surgery, radiotherapy, and chemotherapy.

3.1.    Targeted Therapies
Targeted therapies work by specifically inhibiting molecular pathways that drive tumor growth, proliferation, and survival. One of the earliest examples of targeted therapy in breast cancer is the development of trastuzumab, a monoclonal antibody against the human epidermal growth factor receptor 2 (HER2) protein, which is overexpressed in approximately 20% of breast cancers14. Trastuzumab, in combination with chemotherapy, has significantly improved overall survival for patients with HER2-positive breast cancer15.

Other targeted therapies have been developed for hormone receptor-positive (HR+) breast cancers, which account for approximately 70% of cases16. These therapies include selective estrogen receptor modulators (SERMs), such as tamoxifen, and aromatase inhibitors (AIs), such as anastrozole and letrozole, which block estrogen production or activity and have been shown to improve survival in HR+ breast cancer patients17.
More recently, CDK4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, have been approved for the treatment of advanced HR+/HER2- breast cancer in combination with endocrine therapy18. These drugs inhibit the cell cycle progression, leading to cell cycle arrest and apoptosis, and have been shown to significantly improve progression-free survival and overall survival in patients with advanced disease19.

3.2.    Immunotherapy
Immunotherapy is a rapidly evolving field in cancer treatment, which aims to harness the immune system to recognize and destroy cancer cells. Immune checkpoint inhibitors, such as pembrolizumab and atezolizumab, have shown promising results in the treatment of triple- negative breast cancer (TNBC), a subtype characterized by the absence of estrogen, progesterone, and HER2 receptors, and associated with a poor prognosis20. These drugs target the PD-1/PD-L1 axis, which is involved in the immune evasion of cancer cells, and have been shown to improve overall survival in patients with advanced TNBC21. However, the response rates to immune checkpoint inhibitors in breast cancer are still relatively low, and further research is needed to identify predictive biomarkers and novel immunotherapeutic approaches.

4.    Advances in Breast Cancer Prevention
Breast cancer prevention strategies can be divided into primary prevention, which aims to reduce the incidence of the disease by modifying risk factors, and secondary prevention, which involves early detection and treatment of precancerous lesions or early-stage cancers.

4.1.    Primary Prevention
Lifestyle modifications, such as maintaining a healthy weight, engaging in regular physical activity, limiting alcohol consumption, and adopting a balanced diet, have been shown to reduce the risk of developing breast cancer21. In addition, chemoprevention with SERMs, such as tamoxifen and raloxifene, has been shown to reduce the risk of invasive breast cancer in high-risk women by up to 50%22. However, the use of chemoprevention is limited by concerns about side effects, such as thromboembolic events and endometrial cancer23.

4.2.    Secondary Prevention
Secondary prevention strategies include the identification and management of women with increased breast cancer risk due to genetic mutations, family history, or other factors. For high- risk women, intensive surveillance with annual mammography and breast MRI is recommended, starting at an earlier age than for the general population24. In some cases, prophylactic surgery, such as bilateral mastectomy and/or salpingo- oophorectomy, may be considered to reduce the risk of breast and ovarian cancer in women with BRCA mutations25. However, these interventions carry risks and potential impacts on quality of life, necessitating careful risk-benefit assessment and individualized decision-making.

5.    Challenges and Future Directions
Despite significant advancements in breast cancer research, several challenges remain. One of the major challenges is the management of metastatic breast cancer, which is still considered incurable, with a median overall survival of approximately 3 years26. Novel therapeutic approaches, such as targeted therapies, immunotherapies, and combination regimens, hold promise for improving outcomes in metastatic breast cancer patients. Additionally, research on tumor heterogeneity and the development of resistance to therapy may inform the design of more effective treatment strategies27.

Another challenge is the global disparity in breast cancer outcomes, with women in LMICs experiencing higher mortality rates and lower survival rates compared to their counterparts in HICs28. Efforts to improve breast cancer outcomes in LMICs should focus on strengthening healthcare infrastructure, increasing awareness, and promoting access to affordable and high-quality screening, diagnosis, and treatment services29.
Finally, future research should continue to explore the complex interplay between genetic, environmental, and lifestyle factors in breast cancer etiology, with the aim of identifying novel targets for prevention and therapy. The integration of genomic, transcriptomic, proteomic, and metabolomic data, as well as the application of machine learning and artificial intelligence techniques, may provide new insights into the molecular mechanisms of breast cancer and facilitate the development of personalized medicine approaches30.

6.    The Role of Patient Advocacy and Support
Patient advocacy and support play a crucial role in the overall management of breast cancer, addressing the physical, emotional, social, and financial needs of patients and their families. Patient advocacy groups, such as the Susan G. Komen Foundation and the American Cancer Society, provide valuable resources, including educational materials, financial assistance, and support networks for patients and caregivers31. These organizations also contribute to breast cancer research by raising funds and increasing public awareness of the disease.

The importance of patient-centered care in breast cancer management cannot be overstated, as it has been shown to improve treatment adherence, patient satisfaction, and quality of life32. Integrating psychosocial support and survivorship care planning into routine clinical practice is essential to address the long-term physical and emotional consequences of breast cancer and its treatment, such as fatigue, pain, body image concerns, and fear of recurrence33.

7.    Emerging Technologies in Breast Cancer Research
Emerging technologies have the potential to revolutionize breast cancer research and care. Some notable examples include:

7.1.    Artificial Intelligence and Machine Learning
Artificial intelligence (AI) and machine learning (ML) techniques have shown promise in various aspects of breast cancer research, including early detection, prognosis prediction, and treatment response monitoring. For instance, AI algorithms have been developed to analyze mammography images with high accuracy and consistency, potentially improving the diagnostic performance of breast cancer screening34. ML models have also been used to predict breast cancer survival and recurrence based on clinicopathological and genomic data, which may facilitate personalized treatment planning35.

7.2.    3D Bioprinting
Three-dimensional (3D) bioprinting is an emerging technology that allows for the precise deposition of living cells and biomaterials to create tissue-like structures in vitro. This technology holds potential for the development of patient-specific, multicellular tumor models that closely mimic the in vivo tumor microenvironment, enabling the study of tumor biology and the evaluation of novel therapeutic agents in a more physiologically relevant context36.

7.3.    Nanotechnology
Nanotechnology has the potential to revolutionize breast cancer diagnosis and treatment by enabling the development of targeted drug delivery systems, diagnostic imaging agents, and theranostic platforms that combine diagnostic and therapeutic capabilities37. For example, nanoparticle-based drug carriers have been designed to selectively deliver chemotherapeutic agents to tumor cells, reducing systemic toxicity and improving treatment efficacy38. Additionally, nanoparticles have been used as contrast agents for enhanced imaging of breast cancer, enabling more accurate diagnosis and real-time monitoring of treatment response39.

Conclusion
Breast cancer research has made significant strides over the past few decades, leading to improvements in early detection, treatment, and prevention. However, challenges remain, including the management of metastatic disease, global disparities in outcomes, and the need for a better understanding of breast cancer etiology. Emerging technologies, such as AI, 3D bioprinting, and nanotechnology, hold promise for addressing these challenges and revolutionizing breast cancer care. Continued research efforts, interdisciplinary collaboration, and innovation are essential to further advance our understanding of breast cancer and improve outcomes for patients worldwide.

References
1)    Alwan NAS. Breast Cancer Among Iraqi Women: Preliminary Findings from a Regional Comparative Breast Cancer Research Project. J Glob Oncol. 2016 Mar 16;2(5):255-258. doi: 10.1200/JGO.2015.003087. PMID: 28717711; PMCID: PMC5493264.
2)    Benjamin O. Anderson MD, André M. Ilbawi MD, Nagi S. El Saghir MD., (2014)Breast Cancer in Low and Middle Income Countries (LMICs): A Shifting Tide in Global Health., 2014    Nov    29:21(1):111-118 https://doi.org/10.1111/tbj.12357
3)    Martine Bellanger, Nur Zeinomar, Parisa Tehranifar, and Mary Beth Terry. Are Global Breast Cancer Incidence and Mortality Patterns Related to Country-Specific Economic Development and Prevention Strategies? Journal of Global Oncology 2018 :4, 1-16
4)    Tirona MT, Sehgal R, Ballester O. Prevention of breast cancer (part I): epidemiology, risk factors, and risk assessment tools. Cancer investigation. 2010 Jul 1;28(7):743-50.
5)    Gage M, Wattendorf D, Henry LR. Translational advances regarding hereditary breast cancer syndromes. Journal of surgical oncology. 2012 Apr 1;105(5):444-51.
6)    Bergstrom C, Pence C, Berg J, Partain N, Sadeghi N, Mauer C, Pirzadeh-Miller S, Gao A, Li H, Unni N, Syed S. Clinicopathological features and outcomes in individuals with breast cancer and ATM, CHEK2, or PALB2 mutations. Annals of Surgical Oncology. 2021 Jun;28:3383-93.
7)    Salhab M, Bismohun S, Mokbel K. Risk- reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery. BMC womens health. 2010 Dec;10(1):1-0.
8)    Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S. Report of the international workshop on screening for breast cancer. JNCI: Journal of the National Cancer Institute. 1993 Oct 20;85(20):1644-56.
9)    Kuhl CK. Abbreviated breast MRI for screening women with dense breast: the EA1141 trial. The British Journal of Radiology. 2018 Oct;91(1090):20170441.
10)    Houssami N, Skaane P. Overview of the evidence on digital breast tomosynthesis in breast cancer detection. The Breast. 2013 Apr 1;22(2):101-8.
11)    MARIBS Study Group. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). The Lancet. 2005 May 21;365(9473):1769-78.
12)    Cheng F, Su L, Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget. 2016 Jul 7;7(30):48832.
13)    Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual diseaselatest advances and implications for cure. Nature Reviews Clinical Oncology. 2019 Jul;16(7):409-24.
14)    Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nature clinical practice Oncology. 2006 May 1;3(5):269-80.
15)    Mendes D, Alves C, Afonso N, Cardoso F, Passos-Coelho JL, Costa L, Andrade S, Batel- Marques F. The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer–a systematic review. Breast Cancer Research. 2015 Dec;17(1):1-4.
16)    Mouabbi JA, Raghavendra AS, Bassett Jr RL, Hassan A, Tripathy D, Layman RM. Histology- based survival outcomes in hormone receptor- positive metastatic breast cancer treated with targeted therapies. npj Breast Cancer. 2022 Dec 20;8(1):131.
17)    Robertson JF, Paridaens RJ, Lichfield J, Bradbury I, Campbell C. Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer. European Journal of Cancer. 2021 Mar 1;145:19-28.
18)    Braal CL, Jongbloed EM, Wilting SM, Mathijssen RH, Koolen SL, Jager A. Inhibiting CDK4/6  in  breast  cancer  with  palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs. 2021 Feb;81:317-31.
19)    Vikas P, Borcherding N, Zhang W. The clinical promise of immunotherapy in triple-negative breast cancer. Cancer management and research. 2018;10:6823.
20)    Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Molecular cancer. 2022 Dec;21(1):1-27.
21)    Kushi LH, Doyle C, McCullough M, Rock CL,Demark‐Wahnefried W, Bandera EV, Gapstur S, Patel AV, Andrews K, Gansler T, American Cancer Society 2010 Nutrition and Physical Activity Guidelines Advisory Committee. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA: a cancer journal for clinicians. 2012 Jan;62(1):30-67.
22)    Bao T, Prowell T, Stearns V. Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond. American journal of therapeutics. 2006 Jul 1;13(4):337-48.
23)    Crew KD. Addressing barriers to uptake of breast cancer chemoprevention for patients and providers. American Society of Clinical Oncology Educational Book. 2015 Jan 1;35(1):e50-8.
24)    Monticciolo DL, Newell MS, Moy L, Niell B, Monsees B, Sickles EA. Breast cancer screening in women at higher-than-average risk: recommendations from the ACR. Journal of the American College of Radiology. 2018 Mar 1;15(3):408-14.
25)    Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Annals of Surgical Oncology. 2002 Dec 1;9(10):941-3.
26)    Gnerlich J, Jeffe DB, Deshpande AD, Beers C, Zander C, Margenthaler JA. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988–2003 SEER data. Annals of surgical oncology. 2007 Aug;14:2187-94.
27)    Collins DC, Sundar R, Lim JS, Yap TA. Towards precision medicine in the clinic: from biomarker discovery to novel therapeutics. Trends in pharmacological sciences. 2017 Jan 1;38(1):25-40.
28)    Yip CH, Buccimazza I, Hartman M, Deo SV, Cheung PS. Improving outcomes in breast cancer for low and middle income countries. World journal of surgery. 2015 Mar;39:686- 92.
29)    Pramesh CS, Badwe RA, Bhoo-Pathy N, Booth CM, Chinnaswamy G, Dare AJ, de Andrade VP, Hunter DJ, Gopal S, Gospodarowicz M, Gunasekera S. Priorities for cancer research in low-and middle-income countries: a global perspective. Nature Medicine. 2022 Apr;28(4):649-57.
30)    Picard M, Scott-Boyer MP, Bodein A, Périn O, Droit A. Integration strategies of multi-omics data for machine learning analysis. Computational and Structural Biotechnology Journal. 2021 Jan 1;19:3735-46.
31)    Shelby RA, Taylor KL, Kerner JF, Coleman E, Blum D. The role of community‐based and philanthropic organizations in meeting cancer patient and caregiver needs. CA: A Cancer Journal for Clinicians. 2002 Jul;52(4):229-46.
32)    Step MM, Rose JH, Albert JM, Cheruvu VK, Siminoff LA. Modeling patient-centered communication: oncologist relational communication and patient communication involvement in breast cancer adjuvant therapy decision-making. Patient Education and Counseling. 2009 Dec 1;77(3):369-78.
33)    McCorkle R, Ercolano E, Lazenby M,
Schulman‐Green D, Schilling LS, Lorig K, Wagner EH. Self‐management: Enabling and empowering patients living with cancer as a chronic illness. CA: a cancer journal for clinicians. 2011 Jan;61(1):50-62.
34)    Leibig C, Brehmer M, Bunk S, Byng D, Pinker K, Umutlu L. Combining the strengths of radiologists and AI for breast cancer screening: a retrospective analysis. The Lancet Digital Health. 2022 Jul 1;4(7):e507-19.
35)    Kourou K, Exarchos TP, Exarchos KP, Karamouzis MV, Fotiadis DI. Machine learning applications in cancer prognosis and prediction. Computational and structural biotechnology journal. 2015 Jan 1;13:8-17.
36)    Kim HN, Habbit NL, Su CY, Choi N, Ahn EH, Lipke EA, Kim DH. Microphysiological systems as enabling tools for modeling complexity in the tumor microenvironment and accelerating cancer    drug    development.    Advanced Functional Materials. 2019 May;29(22):1807553.
37)    Caldorera-Moore ME, Liechty WB, Peppas NA. Responsive theranostic systems: integration of diagnostic imaging agents and responsive controlled release drug delivery carriers. Accounts of chemical research. 2011 Oct 18;44(10):1061-70.
38)    Yan L, Shen J, Wang J, Yang X, Dong S, Lu S. Nanoparticle-based drug delivery system: a patient-friendly chemotherapy for oncology. Dose-Response. 2020 Jul 9;18(3):1559325820936161.
39)    Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, O Regan RM. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. The lancet oncology. 2006 Aug 1;7(8):657- 67.
40)    Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., & Iwata, H. (2019). Pembrolizumabmonotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase 2 KEYNOTE-086 study. Annals of Oncology, 30(3), 397-404.
41)    Barenholz, Y. (2012). Doxil®—The first FDA- approved nano-drug: Lessons learned. Journal of Controlled Release, 160(2), 117-134.
42)    Bray, F., Ferlay, J., Soerjomataram, I., Siegel,
R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394-424.
43)    Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F..& Harbeck, N. (2018). 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Annals of Oncology, 29(8), 1634-1657.
44)    Colditz, G. A., &Bohlke, K. (2014). Priorities for the primary prevention of breast cancer. CA: A Cancer Journal for Clinicians, 64(3), 186-194.
45)    Cristofanilli, M., Pierga, J. Y., Reuben, J., Rademaker, A., Davis, A. A., Peeters, D. J.,&Bidard, F. C. (2019). The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Critical Reviews in Oncology/Hematology, 134, 39- 45.
46)    Cuzick, J., Sestak, I., Bonanni, B., Costantino, J. P., Cummings, S., DeCensi, A., ...&Veronesi, U. (2013).    Selective    oestrogen        receptor modulators in prevention of breast cancer: an updated        meta-analysis    of    individual participant data. The Lancet, 381(9880), 1827-1834.
47)    Daly, M. B., Pilarski, R., Yurgelun, M. B., Berry,
M. P., Buys, S. S., Dickson, P. & Hutton, M. L. (2020). NCCN Guidelines® insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal of the National Comprehensive Cancer Network, 18(4), 380-391.
48)        DeSantis, C. E., Ma, J., Gaudet, M. M., Newman, L. A., Miller, K. D., Goding Sauer, A.,
... & Siegel, R. L. (2019). Breast cancer statistics, 2019. CA: A Cancer Journal for Clinicians, 69(6), 438-451.
49)    Early Breast Cancer Trialists\\\\\\\' Collaborative Group. (2015). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. The Lancet, 386(10001)
50)    Pattanayak A., Sonalika S., et al, Early Prediction and Detection of Breast Cancer Using Deep Learning Techniques, International Journal of Early Childhood Special Education (INT-JECS)2022;14(4):1217-1224.